Joindre l'IPC

04 91 22 33 33

 Prendre rendez-vous

04 91 22 30 30

Research is essential but of course the patient is our top priority

Research is essential but of course the patient is our top priority

Our goal, every day, is to turn cancer patients into cancer survivors.

Pr P. VIENS,
Director of IPC

We constantly apply discoveries from the laboratory to improve patients care

We constantly apply discoveries from the laboratory to improve patients care

We also bring what we learn from patients back to the lab to enhance our understanding of basic cancer biology.

Pr N. VEY,
notably Head of the ETOH

We have a bench-to-bedside approach

We have a bench-to-bedside approach

which allows us to move laboratory discoveries swiftly into the patient-care setting, while helping researchers refine therapies and techniques based on clinical observations.

Dr J.F. SAUNIÈRE,
Translational medicine Unit

The CRCM is one of the leading centers of biomedical research in France

The CRCM is one of the leading centers of biomedical research in France

Getting scientists and clinicians to work together on a daily basis to address critical issues in cancer biology.

Pr J.P. BORG,
Director of the CRCM
and Scientific Director of Institut Paoli-Calmettes

Les essais cliniques sont un paramètre essentiel

Les essais cliniques sont un paramètre essentiel

Ils nous permettre de mieux comprendre le cancer et nous aident à développer des traitements plus efficaces et moins toxiques.

Dr D. GENRE,
Responsable du Département de Recherche Clinique et d'innovation

Latest News

Friday 22 June 2018

Brice Chanez reçoit le prix Claude Jacquillat à l'occasion de l'édition 2018 de l'IFODS


More

Event

From Tuesday, Sep 11th 2018 at 01:00 PM
To Tuesday, Sep 11th 2018 at 02:00 PM
Organized by Vincent Géli

Chantal Desdouets


Read more

Highlighted publications

Cancer Research, Molecular Cell, eLife, Nucleic Acids Research, BMC Medical Genomics: our 5 latest publications

Erbin suppresses KSR1-mediated RAS/RAF signaling and tumorigenesis in colorectal...


More

Keynote Lectures

From Friday, Sep 14th 2018 at 11:00 AM
To Friday, Sep 14th 2018 at 02:00 PM
Organized by Jean-Paul Borg

Fred de Sauvage: Tumor Cell Plasticity as a Challenge for Targeted Therapies in Cancer.


Read more

Questions to Jean-Paul Borg, Scientific Director of IPC

Introduction to research activities with Jean-Paul Borg, Scientific Director of Institut Paoli-Calmettes

What is distinctive about an institute like ours is the combination of research and care in one place.

The goal of the reorganization of our research, effective in 2012, is to bring even closer all players contributing to the advancement of our discipline: the discoverers of the targets of basic research, translational research experts that guide these discoveries to applications, oncologists and personnel that evaluate the efficacy and safety in clinical development of these new treatments and to make available the 80,000 samples of our biobank and the best technology and engineering. In practical terms this also means:

  • A new building that houses nearly one hundred researchers from CNRS, INSERM, the IPC and the new Aix-Marseille University.
  • A new team dedicated to translational research and evaluation of therapeutic drug candidates.
  • New tools such as the platform for preclinical evaluation TrGET ® or the unit dedicated to early clinical trials, ETOH.
  • New vocations: project manager, research organizer, research nurse...
  • Exploring new avenues of research, such as mechanisms of DNA repair or the relationship between cellular stress and cancer.
  • Finally, a new project-based organization that promotes the emergence of innovative approaches in areas of historical expertise of the Institute: hematologic malignancies, breast, digestive and urogenital cancers.

If we want to advance our knowledge in oncology it is imperative that research be closely involved in the care of patients.

This is because research in the IPC is first and foremost determined by the needs of the oncologist and his patient but also because the manner in which the patient responds to treatment is full of information for the researcher, whether he is oriented to fundamental or more applied studies. In this way, when a patient is resistant to treatment, the researcher quickly explores the biological peculiarities of the tumor to identify a potential biomarker associated with this resistance. Once validated, this biomarker will be used by the oncologist to stratify patients and use this treatment only for patients who may benefit from it.

Of course, the strength of the IPC is its scientific and medical excellence and advanced technology but also the constant questioning and the collaborative culture that make possible the continuous back and forth interaction between biology and the clinic.

A new building houses nearly one hundred researchers

 

L'IPC et le réseau européen Oncodistinct

logo réseau européen oncodistinct

Le réseau Européen Oncodistinct a pour but de répondre de façon dynamique et efficace aux changements rapides et exponentiels qui caractérisent la recherche clinique en oncologie.  

Il s'agit d'accélérer l'individualisation des traitements,  de promouvoir la prise en charge multidisciplinaire des cancers et de remettre en question les pratiques actuelles, notamment dans les situations de besoins médicaux  non satisfaits ou de tumeurs rares. 

Le réseau comprend aujourd'hui 27 membres, Centres de lutte contre le cancer et hôpitaux universitaires, dotés d'une expertise en oncologie et dans le développement des médicaments anti-cancéreux. La mise en commun des expertises scientifiques (médecins oncologues et spécialistes d'organes, chercheurs) améliore la qualité des études, la bonne collaboration entre les centres et la rapidité de réalisation des projets.  

Oncodistinct souhaite développer des essais cliniques  de phases précoce ou plus avancée, « preuve de concept », utilisant des méthodologies innovantes et avec une composante translationnelle de haut niveau, avec l'objectif final d'améliorer significativement le devenir des patients. 

Oncodistinct a également pour projet de travailler en partenariat avec les patients pour répondre au mieux à leurs besoins.


Rendez-vous sur le site http://www.oncodistinct.net/ pour en savoir plus.